Market research
PRVB Provention Bio Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 23.5
- Dividend yield
- 0.0%
- Beta
- 2.46
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74374N1028
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 23.5
- Dividend yield
- 0.0%
- Beta
- 2.46
About
About Provention Bio Inc
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PRVB discussion.
5 years, 4 months ago
Provention Bio, Inc is currently in a long term downtrend where the price is trading 49.3% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Provention Bio, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 209.1% to $-33M since the same quarter in the previous year.
Finally, its free cash flow fell by 160.6% to $-25M since the same quarter in the previous year.
Based on the above factors, Provention Bio, Inc gets an overall score of 1/5.